CYP2C19 and major depressive disorder: SSRIs are the first-line treatment for major depressive disorders but it has been estimated that 50% of these patients will fail to respond to the initial treatment [46] and hence, SSRIs dosing recommendation based on CYP2C19 genotype could potentially improve treatment outcome and minimize the occurrence of side effects.